Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003417 · ClinicalTrials.gov registry record · Phase 1
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT00003417 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 40 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT00003417, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor in order to plan treatment may result in more effective radiation therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy that has been planned with a computer plus chemotherapy in treating patients who have glioblastoma multiforme.
Conditions Studied
Interventions
- RADIATION radiation therapy
- DRUG carmustine
Study Locations (20)
California
- Mount Diablo Medical Center - Concord
- City of Hope Comprehensive Cancer Center - Duarte
- Saint Agnes Cancer Center - Fresno
- California Cancer Center - Fresno
- Sutter Health Western Division Cancer Research Group - Greenbrae
- Loma Linda University Medical Center - Loma Linda
- Veterans Affairs Medical Center - Long Beach - Long Beach
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- CCOP - Bay Area Tumor Institute - Oakland
- Huntington Cancer Center - Pasadena
- Robert and Beverly Lewis Family Cancer Care Center - Pomona
- Radiation Oncology Center - Sacramento - Sacramento
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
- Comprehensive Cancer Institute of Huntsville - Huntsville
- Huntsville Hospital System - Huntsville
- MBCCOP - Gulf Coast - Mobile
- Alabama Oncology, LLC - Montgomery
- DCH Cancer Treatment Center - Tuscaloosa
Arizona
- Foundation for Cancer Research and Education - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1998-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003417
The ClinicalTrials.gov registry entry for NCT00003417 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (78% lower). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which radiation therapy is the first listed.
NCT00003417 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00003417 about?
NCT00003417 is a clinical study titled "Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor in order to plan treatment may result in more effective radiation therapy. Drugs used in chemotherapy use different ways to stop tumor cells ...
What is the current status of trial NCT00003417?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 1998-09.
What conditions does trial NCT00003417 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00003417?
The interventions under investigation include: radiation therapy (RADIATION), carmustine (DRUG).
Who is sponsoring clinical trial NCT00003417?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003417 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.